Compare · AVTR vs TXG
AVTR vs TXG
Side-by-side comparison of Avantor Inc. (AVTR) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $7.56B, about 1.4x TXG ($5.55B).
- Over the past year, AVTR is down 16.8% and TXG is up 260.2% - TXG leads by 277.0 points.
- AVTR has been more active in the news (5 items in the past 4 weeks vs 2 for TXG).
- Both have 25 recent analyst ratings on file.
- Company
- Avantor Inc.
- 10x Genomics Inc.
- Price
- $11.06-1.78%
- $43.75-1.73%
- Market cap
- $7.56B
- $5.55B
- 1M return
- +15.45%
- +37.75%
- 1Y return
- -16.78%
- +260.23%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2019
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 25
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest AVTR
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
- Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
- Bernstein resumed coverage on Avantor with a new price target
- President, VWR Dist. & Servs. Walker Corey covered exercise/tax liability with 3,010 shares, decreasing direct ownership by 0.78% to 384,535 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest TXG
- 10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Chief Executive Officer Saxonov Serge sold $1,033,269 worth of shares (30,000 units at $34.44) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,108,380 units (SEC Form 4)
- IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist
- Director Suliman Shehnaaz sold $186,756 worth of shares (5,723 units at $32.63) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 31,722 units (SEC Form 4)
- 10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
- SEC Form 144 filed by 10x Genomics Inc.
- 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
- Director Teichmann Sarah A. was granted 8,829 shares, increasing direct ownership by 33% to 35,609 units (SEC Form 4)
- Director Suliman Shehnaaz was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)
- Director Stuelpnagel John R was granted 8,829 shares, increasing direct ownership by 2% to 368,436 units (SEC Form 4)